≡

Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)

EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT

  • Product No.RPC615Hu01
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane, Nucleus, Mitochondrion, Cytoplasm
  • Predicted Molecular Mass38.3kDa
  • Accurate Molecular Mass38kDa(Analysis of differences refer to the manual)
  • Residues & TagsArg6~Ile328 with N-terminal His Tag
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder
  • Purity> 90%
  • Isoelectric Point5.2
  • Applications Positive Control; Immunogen; SDS-PAGE; WB.
    If bio-activity of the protein is needed, please check active protein.
  • DownloadInstruction Manual
  • UOM 10µg50µg 200µg 1mg 5mg
  • FOB US$ 172  US$ 430  US$ 860  US$ 2580  US$ 6450 
    For more details, please contact local distributors!

SEQUENCE

USAGE

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
ACTA NEUROPATHOLOGICA COMMUNICATIONS Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma Pubmed: 32410663
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPC615Hu01 Recombinant Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Positive Control; Immunogen; SDS-PAGE; WB.
PAC615Hu01 Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) WB; IHC; ICC; IP.
FAC615Hu01 Anti-Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Polyclonal Antibody Flow cytometry.
MAC615Hu22 Monoclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) WB; IHC; ICC; IP.
SEC615Hu ELISA Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) Enzyme-linked immunosorbent assay for Antigen Detection.
LMC615Hu Multiplex Assay Kit for Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.